. Author manuscript; available in PMC: 2016 Mar 4.

Published in final edited form as: Curr Opin Otolaryngol Head Neck Surg. 2012 Oct;20(5):372–379. doi: 10.1097/MOO.0b013e328357d2ee

Table 2.

Drugs in development for neurofibromatosis type 2

Drug	Mechanism	Stage of development	Target tumor
Lapatinib	Oral small tyrosine kinase receptor inhibitor of EGFR/Erb2	Phase 0	Vestibular schwannoma
		Phase 2
RAD001 (Everolimus)	Oral mTOR inhibition	Phase 0	Vestibular schwannoma
		Phase 2	Meningioma
Bevacizumab	Intravenous monoclonal antibody against vascular endothelial growth factor (VEGF)	Phase 2	Vestibular schwannoma
Nilotinib	Oral multitarget kinase inhibitor including Bcr-Abl, c-kit, PDGFRbeta	Phase 0	Cutaneous schwannomas
AR-42	Oral histone deacetylase inhibitor	Phase 0	Vestibular schwannoma
		Phase 1	Meningioma